In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thanks to FASB, Alliances Just Got More Expensive

Executive Summary

The latest cause of financial angst in biotech is FIN 46, the new accounting rule that could force drug companies to consolidate the expenses of their biotech partners, whether they own significant equity stakes or not. What will this affect? How about: any joint ventures, any co-development deals, and co-promotion, any R&D funding contracts-even, possibly, distribution and supply contracts.
Advertisement

Related Content

Dealmaking When Pharma's the Only Game in Town
Dealmaking When Pharma's the Only Game in Town
Synosis: the Financial Leverage of Translational Medicine
Metabolex and J&J: Why Biotech's Pipelines Needs Pharma's
Will a New Accounting Change Cut Acquisition Values?
The FASB Nightmare

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel